These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 33269951

  • 1. Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension.
    Lipton RB, Tepper SJ, Silberstein SD, Kudrow D, Ashina M, Reuter U, Dodick DW, Zhang F, Rippon GA, Cheng S, Mikol DD.
    Cephalalgia; 2021 Jan; 41(1):6-16. PubMed ID: 33269951
    [Abstract] [Full Text] [Related]

  • 2. Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study.
    Tepper SJ, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein SD, Winner P, Zhang F, Cheng S, Mikol DD.
    Cephalalgia; 2020 May; 40(6):543-553. PubMed ID: 32216456
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J.
    Lancet; 2018 Nov 24; 392(10161):2280-2287. PubMed ID: 30360965
    [Abstract] [Full Text] [Related]

  • 4. Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies.
    Lipton RB, Dodick DW, Kudrow D, Reuter U, Tenenbaum N, Zhang F, Lima GPDS, Chou DE, Mikol DD.
    Cephalalgia; 2021 Dec 24; 41(14):1458-1466. PubMed ID: 34407654
    [Abstract] [Full Text] [Related]

  • 5. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
    Tepper SJ, Ashina M, Reuter U, Hallström Y, Broessner G, Bonner JH, Picard H, Cheng S, Chou DE, Zhang F, Klatt J, Mikol DD.
    J Headache Pain; 2021 Jul 23; 22(1):81. PubMed ID: 34301173
    [Abstract] [Full Text] [Related]

  • 6. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination.
    Raffaelli B, Mussetto V, Israel H, Neeb L, Reuter U.
    J Headache Pain; 2019 Jun 03; 20(1):66. PubMed ID: 31159727
    [Abstract] [Full Text] [Related]

  • 7. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
    Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Cheng S, Numachi Y, Peng C, Xue F, Mikol DD.
    Headache; 2021 Apr 03; 61(4):653-661. PubMed ID: 33764538
    [Abstract] [Full Text] [Related]

  • 8. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study.
    Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, Gage JR, Cheng S, Mikol DD, Lenz RA.
    Neurology; 2017 Sep 19; 89(12):1237-1243. PubMed ID: 28835404
    [Abstract] [Full Text] [Related]

  • 9. Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial.
    Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J, Wen S, Hours-Zesiger P, Nickisch J, Sieder C, Hentschke C, Maier-Peuschel M.
    Cephalalgia; 2022 Feb 19; 42(2):108-118. PubMed ID: 34743579
    [Abstract] [Full Text] [Related]

  • 10. Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study.
    Wang SJ, Kim BK, Wang H, Zhou J, Wan Q, Yu T, Lian Y, Arkuszewski M, Ecochard L, Snellman J, Wen S, Yin F, Li Z, Su W, Yu S.
    Headache; 2024 May 24. PubMed ID: 38785393
    [Abstract] [Full Text] [Related]

  • 11. Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.
    Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick D, Rippon GA, Klatt J, Xue F, Chia V, Zhang F, Cheng S, Mikol DD.
    Cephalalgia; 2019 Oct 24; 39(11):1455-1464. PubMed ID: 31146544
    [Abstract] [Full Text] [Related]

  • 12. Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycle.
    Dodick DW, Blumenfeld AM, Halker Singh RB, Williams R, Zhang F, Chen PW, Hsu CP, Peng C, Snellman J, Chehrenama M, Ailani J.
    Headache; 2023 Feb 24; 63(2):233-242. PubMed ID: 36226464
    [Abstract] [Full Text] [Related]

  • 13. Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studies.
    Hirata K, Takeshima T, Sakai F, Imai N, Matsumori Y, Tatsuoka Y, Numachi Y, Yoshida R, Peng C, Mikol DD, Lima GPDS, Cheng S.
    Brain Behav; 2022 Mar 24; 12(3):e2526. PubMed ID: 35201674
    [Abstract] [Full Text] [Related]

  • 14. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R, Salerno A, Torelli P, Albanese M, Carnevale A, Bono F, D'Amico D, Filippi M, Altamura C, Vernieri F, EARLY Study Group.
    Headache; 2021 Oct 24; 61(9):1351-1363. PubMed ID: 34309862
    [Abstract] [Full Text] [Related]

  • 15. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study.
    Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Wright IK, Chou DE, Klatt J, Picard H, Lenz RA, Mikol DD.
    Neurology; 2020 Aug 04; 95(5):e469-e479. PubMed ID: 32636324
    [Abstract] [Full Text] [Related]

  • 16. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
    Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, Peng C, Cheng S, Mikol DD.
    Headache; 2021 Jun 04; 61(6):927-935. PubMed ID: 34153117
    [Abstract] [Full Text] [Related]

  • 17. Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials.
    Lampl C, Kraus V, Lehner K, Loop B, Chehrenama M, Maczynska Z, Ritter S, Klatt J, Snellman J.
    J Headache Pain; 2022 Aug 18; 23(1):104. PubMed ID: 35978286
    [Abstract] [Full Text] [Related]

  • 18. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.
    Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA.
    Cephalalgia; 2018 May 18; 38(6):1026-1037. PubMed ID: 29471679
    [Abstract] [Full Text] [Related]

  • 19. Assessment of prolonged safety and tolerability of erenumab in migraine patients in a long-term open-label study (APOLLON).
    Göbel H, Schlegel E, Jaeger K, Ortler S, Leist L.
    J Headache Pain; 2024 Sep 25; 25(1):157. PubMed ID: 39322961
    [Abstract] [Full Text] [Related]

  • 20. Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
    Tepper SJ, Lipton RB, Silberstein SD, Kudrow D, Ashina M, Reuter U, Dodick DW, Wang A, Cheng S, Klatt J, Mikol DD.
    Headache; 2023 Jun 25; 63(6):730-742. PubMed ID: 37313616
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.